DDInter624 DDInter1261
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Amiodarone
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Cytochrome P450 2C9 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Amiodarone
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Amiodarone
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Efavirenz {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Amiodarone
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Cytochrome P450 2C9 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Griseofulvin
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Efavirenz {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Nelfinavir
Nelfinavir {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Verapamil
Verapamil {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound) and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Efavirenz (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Amiodarone (Compound) and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Amiodarone (Compound) and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Efavirenz (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Amiodarone (Compound) and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Efavirenz (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may lead to a major life threatening interaction when taken with Naloxegol
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Griseofulvin (Compound) and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Efavirenz (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Nelfinavir (Compound) and Nelfinavir may lead to a major life threatening interaction when taken with Naloxegol
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Verapamil (Compound) and Verapamil may lead to a major life threatening interaction when taken with Naloxegol